Literature DB >> 17415506

Accrual of organ damage over time in Argentine patients with systemic lupus erythematosus: a multi-centre study.

Gustavo Cassano1, Susana Roverano1, Sergio Paira2, Verónica Bellomio3, Eleonora Lucero3, Alberto Berman3, Alberto Spindler3, Rosana Trobo4, Luis Fernando Somma5, César Graf6, Alejandra Barrionuevo7, Silvia Papasidero7, Oscar Rillo7.   

Abstract

The goals of this study were to ascertain damage in patients with systemic lupus erythematosus (SLE) from five rheumatologic centres in Argentina and to examine overall damage, damage by domain and damage by item within each domain. We performed a retrospective observational study including patients with SLE (ACR 1997 revised and modified criteria) from five rheumatology centres in Argentina. Organ damage was scored using the SLICC/ACR DI (SDI), ascertained at years 1, 2, 5 and 10. Three centres provided information up to the fifth year. Of the 197 patients, 88.3% were women and their mean age was 33.2 years. The mean disease duration and follow-up were 7.6 and 5.3 years, respectively. Damage accrued gradually over time with SDI ranging from 0.52 (+/-1.1) at year 1 up to 2.46 (+/-2.1) at year 10. The renal system was the most involved system, followed by the neuropsychiatric, the cardiovascular and the musculoskeletal systems. Proteinuria, cognitive impairment, pericarditis, avascular necrosis, cataract and alopecia were the predominant items in their respective systems. Systems such as peripheral vascular, pulmonary, gastrointestinal, diabetes, malignancy and premature gonadal failure were not frequent. Overall SDI had a gradual increase over time. Damage in each domain of SDI, except for diabetes, had a similar behaviour. Behaviour of items in each domain varied.

Entities:  

Mesh:

Year:  2007        PMID: 17415506     DOI: 10.1007/s10067-007-0604-3

Source DB:  PubMed          Journal:  Clin Rheumatol        ISSN: 0770-3198            Impact factor:   2.980


  23 in total

1.  Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus.

Authors:  M C Hochberg
Journal:  Arthritis Rheum       Date:  1997-09

2.  Mortality studies in systemic lupus erythematosus. Results from a single center. III. Improved survival over 24 years.

Authors:  M B Urowitz; D D Gladman; M Abu-Shakra; V T Farewell
Journal:  J Rheumatol       Date:  1997-06       Impact factor: 4.666

Review 3.  Systemic lupus erythematosus.

Authors:  J A Mills
Journal:  N Engl J Med       Date:  1994-06-30       Impact factor: 91.245

Review 4.  Indicators of disease activity, prognosis, and treatment of systemic lupus erythematosus.

Authors:  D D Gladman
Journal:  Curr Opin Rheumatol       Date:  1993-09       Impact factor: 5.006

5.  The bimodal mortality pattern of systemic lupus erythematosus.

Authors:  M B Urowitz; A A Bookman; B E Koehler; D A Gordon; H A Smythe; M A Ogryzlo
Journal:  Am J Med       Date:  1976-02       Impact factor: 4.965

6.  Accrual of organ damage over time in patients with systemic lupus erythematosus.

Authors:  Dafna D Gladman; Murray B Urowitz; Proton Rahman; Dominique Ibañez; Lai-Shan Tam
Journal:  J Rheumatol       Date:  2003-09       Impact factor: 4.666

7.  High impact of antiphospholipid syndrome on irreversible organ damage and survival of patients with systemic lupus erythematosus.

Authors:  Guillermo Ruiz-Irastorza; Maria-Victoria Egurbide; Jon Ugalde; Ciriaco Aguirre
Journal:  Arch Intern Med       Date:  2004-01-12

Review 8.  The development and initial validation of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology damage index for systemic lupus erythematosus.

Authors:  D Gladman; E Ginzler; C Goldsmith; P Fortin; M Liang; M Urowitz; P Bacon; S Bombardieri; J Hanly; E Hay; D Isenberg; J Jones; K Kalunian; P Maddison; O Nived; M Petri; M Richter; J Sanchez-Guerrero; M Snaith; G Sturfelt; D Symmons; A Zoma
Journal:  Arthritis Rheum       Date:  1996-03

9.  Mortality studies in systemic lupus erythematosus. Results from a single center. I. Causes of death.

Authors:  M Abu-Shakra; M B Urowitz; D D Gladman; J Gough
Journal:  J Rheumatol       Date:  1995-07       Impact factor: 4.666

10.  Analysis of the relationship between disease activity and damage in patients with systemic lupus erythematosus--a 5-yr prospective study.

Authors:  T Stoll; N Sutcliffe; J Mach; R Klaghofer; D A Isenberg
Journal:  Rheumatology (Oxford)       Date:  2004-05-25       Impact factor: 7.580

View more
  10 in total

Review 1.  A review on SLE and malignancy.

Authors:  May Y Choi; Kelsey Flood; Sasha Bernatsky; Rosalind Ramsey-Goldman; Ann E Clarke
Journal:  Best Pract Res Clin Rheumatol       Date:  2017-11-10       Impact factor: 4.098

2.  Chronic high-dose glucocorticoid therapy triggers the development of chronic organ damage and worsens disease outcome in systemic lupus erythematosus.

Authors:  Tünde Tarr; Gábor Papp; Nikolett Nagy; Edina Cserép; Margit Zeher
Journal:  Clin Rheumatol       Date:  2016-11-26       Impact factor: 2.980

3.  Prevalence and incidence of systemic lupus erythematosus in South Korea.

Authors:  Jee-Seon Shim; Yoon-Kyoung Sung; Young Bin Joo; Hye-Soon Lee; Sang-Cheol Bae
Journal:  Rheumatol Int       Date:  2013-12-10       Impact factor: 2.631

4.  Damage extent and predictors in adult and juvenile dermatomyositis and polymyositis as determined with the myositis damage index.

Authors:  Lisa G Rider; Peter A Lachenbruch; Jason B Monroe; Angelo Ravelli; Imelda Cabalar; Brian M Feldman; Maria L Villalba; Barry L Myones; Lauren M Pachman; Robert M Rennebohm; Ann M Reed; Frederick W Miller
Journal:  Arthritis Rheum       Date:  2009-11

Review 5.  Damage assessment in ANCA-associated vasculitis.

Authors:  Kuljeet Bhamra; Raashid Luqmani
Journal:  Curr Rheumatol Rep       Date:  2012-12       Impact factor: 4.592

6.  Peripheral vascular damage in systemic lupus erythematosus: data from LUMINA, a large multi-ethnic U.S. cohort (LXIX).

Authors:  P I Burgos; L M Vilá; J D Reveille; G S Alarcón
Journal:  Lupus       Date:  2009-10-22       Impact factor: 2.911

7.  Analysis of brain metabolites by gas chromatography-mass spectrometry reveals the risk-benefit concerns of prednisone in MRL/lpr lupus mice.

Authors:  Jia Zhou; Feilong Lu; Shan Li; Meijuan Xie; Haimei Lu; Zhijun Xie; Dehong Wu; Shuang Wang; Chengping Wen; Zheng-Hao Xu
Journal:  Inflammopharmacology       Date:  2019-11-30       Impact factor: 4.473

8.  Drug utilization and therapy provision patterns by prescriber types among patients with systemic lupus erythematosus in Korea.

Authors:  Sooyoung Shin
Journal:  Patient Prefer Adherence       Date:  2017-10-17       Impact factor: 2.711

9.  Impact of glucocorticoids on the incidence of lupus-related major organ damage: a systematic literature review and meta-regression analysis of longitudinal observational studies.

Authors:  Manuel Francisco Ugarte-Gil; Anselm Mak; Joanna Leong; Bhushan Dharmadhikari; Nien Yee Kow; Cristina Reátegui-Sokolova; Claudia Elera-Fitzcarrald; Cinthia Aranow; Laurent Arnaud; Anca D Askanase; Sang-Cheol Bae; Sasha Bernatsky; Ian N Bruce; Jill Buyon; Nathalie Costedoat-Chalumeau; Mary Ann Dooley; Paul R Fortin; Ellen M Ginzler; Dafna D Gladman; John Hanly; Murat Inanc; David Isenberg; Soren Jacobsen; Judith A James; Andreas Jönsen; Kenneth Kalunian; Diane L Kamen; Sung Sam Lim; Eric Morand; Marta Mosca; Christine Peschken; Bernardo A Pons-Estel; Anisur Rahman; Rosalind Ramsey-Goldman; John Reynolds; Juanita Romero-Diaz; Guillermo Ruiz-Irastorza; Jorge Sánchez-Guerrero; Elisabet Svenungsson; Murray Urowitz; Evelyne Vinet; Ronald F van Vollenhoven; Alexandre Voskuyl; Daniel J Wallace; Michelle A Petri; Susan Manzi; Ann Elaine Clarke; Mike Cheung; Vernon Farewell; Graciela S Alarcon
Journal:  Lupus Sci Med       Date:  2021-12

10.  Factors associated with damage accrual in patients with systemic lupus erythematosus: results from the Systemic Lupus International Collaborating Clinics (SLICC) Inception Cohort.

Authors:  Ian N Bruce; Aidan G O'Keeffe; Vern Farewell; John G Hanly; Susan Manzi; Li Su; Dafna D Gladman; Sang-Cheol Bae; Jorge Sanchez-Guerrero; Juanita Romero-Diaz; Caroline Gordon; Daniel J Wallace; Ann E Clarke; Sasha Bernatsky; Ellen M Ginzler; David A Isenberg; Anisur Rahman; Joan T Merrill; Graciela S Alarcón; Barri J Fessler; Paul R Fortin; Michelle Petri; Kristjan Steinsson; Mary Anne Dooley; Munther A Khamashta; Rosalind Ramsey-Goldman; Asad A Zoma; Gunnar K Sturfelt; Ola Nived; Cynthia Aranow; Meggan Mackay; Manuel Ramos-Casals; Ronald F van Vollenhoven; Kenneth C Kalunian; Guillermo Ruiz-Irastorza; Sam Lim; Diane L Kamen; Christine A Peschken; Murat Inanc; Murray B Urowitz
Journal:  Ann Rheum Dis       Date:  2014-05-16       Impact factor: 19.103

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.